Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr 1;116(7):1638-45.
doi: 10.1002/cncr.24953.

Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules

Affiliations
Review

Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules

Jing Yang et al. Cancer. .

Abstract

Targeted antibody-based therapy has been used successfully to treat cancers. Recent studies have demonstrated that tumor cells treated with antibodies specific for beta(2)-microglobulin (beta(2)M) or major histocompatibility complex (MHC) class I molecules undergo apoptosis in vitro and in vivo (mouse models). Antibodies against beta(2)M or MHC class I induce tumor cell apoptosis by 1) recruiting MHC class I molecules to lipid rafts and activating LYN kinase and the signal-transducing enzyme phospholipase C-gamma2-dependent c-Jun N-terminal kinase signaling pathway and 2) expelling interleukin 6 and insulin-like growth factor 1 receptors out of lipid rafts and inhibiting the growth and survival factor-induced activation of the phosphatidylinositol 3-kinase/Akt and extracellular signal-related kinase pathways. Consequently, mitochondrial integrity is compromised, and the caspase-9-dependent cascade is activated in treated tumor cells. However, although beta(2)M and MHC class I are expressed on normal hematopoietic cells, which is a potential safety concern, the monoclonal antibodies were selective to tumor cells and did not damage normal cells in vitro or in human-like mouse models. These findings suggest that targeting beta(2)M or MHC class I by using antibodies or other agents offers a potential therapeutic approach for beta(2)M/MHC class I-expressing malignancies. Cancer 2010. (c) 2010 American Cancer Society.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

Figures

Figure 1
Figure 1
Anti-β2M mAb-mediated apoptotic signaling pathways in myeloma cells.

Similar articles

Cited by

References

    1. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952–961. - PubMed
    1. Buus S. MHC restricted antigen presentation and T cell recognition. Dan Med Bull. 1994;41:345–358. - PubMed
    1. Bjorkman PJ, Burmeister WP. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Curr Opin Struct Biol. 1994;4:852–856. - PubMed
    1. Strominger JL. Human histocompatibility proteins. Immunol Rev. 2002;185:69–77. - PubMed
    1. Natarajan K, Li H, Mariuzza RA, et al. MHC class I molecules, structure and function. Rev Immunogenet. 1999;1:32–146. - PubMed

Publication types

Substances